Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS ...

Loomis Sayles & Co. has gone all in on Regeneron Pharmaceuticals, boosting its stake by 393,997 shares in Q4. This leap now ...

UniSuper Management Pty Ltd turned up the financial charm, upping its Regeneron stake by 38% in Q4. The fund now owns 7,306 ...

Q4 results today: According to market experts, the banking sector is predicted to outperform market estimates, while other segments may face pressure from increased provisioning due to concerns ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other most profitable biotech stocks to buy right now. With improved market ...

In that sense, Gilead (GILD) with lenacapavir and Regeneron (REGN) with Eylea label expansion and new formulation “theoretically have the most risk,” followed by Merck (MRK) with subcutaneous ...

We recently compiled a list of the 10 Best EV Stocks to Buy Under $50. In this article, we are going to take a look at where ...

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...